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Abstract
Calcium phosphate is the most important inorganic constituent of biological tissues, and synthetic calcium
phosphate has been widely used as biomaterials. In this study, a facile method has been developed for the
fabrication of amorphous calcium phosphate (ACP)/polylactide-block-monomethoxy(polyethyleneglycol) hybrid
nanoparticles and ACP porous nanospheres. Europium-doping is performed to enable photoluminescence (PL)
function of ACP porous nanospheres. A high specific surface area of the europium-doped ACP (Eu
3+:ACP) porous
nanospheres is achieved (126.7 m
2/g). PL properties of Eu
3+:ACP porous nanospheres are investigated, and the
most intense peak at 612 nm is observed at 5 mol% Eu
3+ doping. In vitro cytotoxicity experiments indicate that
the as-prepared Eu
3+:ACP porous nanospheres are biocompatible. In vitro drug release experiments indicate that
the ibuprofen-loaded Eu
3+:ACP porous nanospheres show a slow and sustained drug release in simulated body
fluid. We have found that the cumulative amount of released drug has a linear relationship with the natural
logarithm of release time (ln(t)). The Eu
3+:ACP porous nanospheres are bioactive, and can transform to
hydroxyapatite during drug release. The PL properties of drug-loaded nanocarriers before and after drug release
are also investigated.
Introduction
The development of multifunctional nanosystems, for
maximum therapeutic benefit including early diagnoses
of the diseases and delivery of suitable therapeutic
drugs, holds a promise for the future of clinical treat-
ment to enhance therapeutic efficacy [1,2]. Therefore, it
is highly desirable to develop novel methods that can
achieve simultaneous in vivo imaging and treatment
based on nanotechnology. Nanoparticles show unique
size-dependant physical and chemical properties and
have great potential for clinical use [3,4]. Dual or multi-
functional nanosystems can be constructed based on
nanostructures with well-designed structures and consti-
tuents, which are simultaneously capable of diagnosis
and treatment [5]. Many kinds of nanostructures have
been fabricated from a multitude of materials and used
in bio-imaging, including quantum dots [6-8], silica
particles [9], gold [10], carbon nanotubes [11], dendri-
mers [12-14], magnetic nanoparticles [15-18], and so on.
However, in the search for the nanosystems for bio-ima-
ging and therapy, a couple of the major concerns are
their biodegradability and toxicity [19-21]. To date, the
development of multifunctional inorganic nanosystems
with both biocompatible and biodegradable properties
has been little reported, and more research is needed in
this regard.
Calcium phosphates including hydroxyapatite (HAp)
are the most important inorganic constituents of biolo-
gical tissues such as bone and tooth [22-25]. Thus, syn-
thetic calcium phosphates are of great significance
because of their biodegradability and biocompatibility,
and have been investigated for applications in bone
repair/tissue engineering [26,27], drug loading and
release [28,29], gene delivery [30,31], and other biomedi-
cal areas. Owing to its chemical nature, calcium phos-
phate nanostructures may serve as an ideal candidate
for both bio-imaging and drug delivery. The investiga-
tion on rare earth-doped calcium phosphates has
become a hot research topic [32-37]. However, up to
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tional calcium phosphate nanostructures for biomedical
applications. HAp, a kind of chemically stable calcium
phosphate, has been used for drug storage and lumines-
cence [38]. The development of bi-functional nanosys-
tems of other calcium phosphates such as amorphous
calcium phosphate (ACP) is still scarce. Compared with
HAp, ACP is bioactive with better biodegradability, and
can promote osteoblast adhesion and osteoconductivity
[39,40].
In this article, the authors report a facile method for
the fabrication of ACP/polylactide-block-monomethoxy
(polyethyleneglycol) (PLA-mPEG) hybrid nanoparticles
and ACP porous nanospheres. ACP is an important
kind of calcium phosphate and is present in natural
bone [41]. PEG and PLA are widely used as biocompati-
ble polymers and currently possess the approval of the
US Food and Drug Administration for use in a variety
of biomaterials applications [42,43]. Europium doping
was performed to enable photoluminescence (PL) func-
tion of ACP porous nanospheres. In vitro cytotoxicity
e x p e r i m e n t ss h o w e dt h a tt h ea s - p r e p a r e dp o r o u sn a n o -
spheres were biocompatible. In vitro drug loading and
release experiments indicated that ibuprofen-loaded
europium-doped ACP (Eu
3+:ACP) porous nanospheres
had a slow and sustained drug release profile in simu-
lated body fluid (SBF). The cumulative amount of the
released drug had a linear relationship with the natural
logarithm of release time (ln(t)). The Eu
3+:ACP porous
nanospheres were bioactive, and could transform to
HAp after drug release.
Experimental conditions
The block copolymer PLA-mPEG (Mw = 8000 Da) was
purchased from Jinan Daigang Co., Ltd., Jinan, China, and
the molecular weight of the PEG segment was 5000 Da.
Other chemicals were purchased from Sinopharm Chemi-
cal Reagent Co., Shanghai, China, and used as received
without further purification. For the preparation of ACP/
PLA-mPEG hybrid nanoparticles, 1.775 g of Na2HPO4
12H2O and 0.025 g of PLA-mPEG was dissolved in 60 mL
of distilled water, and the pH value was adjusted to 10
using ammonia, followed by magnetic stirring for 1 h to
form a clear solution. Then, 60 mL of calcium chloride
aqueous solution containing 0.33 g of CaCl2 and 0.025 g
of PLA-mPEG was added dropwise (10 mL/min) to the
above solution, and the pH value was maintained at 10 by
slow addition of ammonia. The white precipitate was col-
lected and washed by centrifugation-redispersion cycles
with distilled water and ethanol. For the preparation of
ACP porous nanospheres, 0.1 g of the as-obtained precipi-
tate was transferred into a 70-mL Teflon autoclave with
50 mL N, N-dimethylformamide (DMF) and treated
at 200°C for 1 h by a microwave-solvothermal system
(MDS-10, Sineo, Shanghai,C h i n a ) .T h ep r o d u c tw a s
washed with distilled water and ethanol and dried at 60°C.
For the preparation of europium-doped Eu
3+:ACP porous
nanospheres, europium nitrate aqueous solution was
added into the calcium source solution before mixing with
phosphate source solution. The doping concentration of
Eu
3+ was 1, 5, and 10 mol% relative to Ca
2+.
PL measurements of Eu
3+:ACP porous nanospheres
were carried out on a spectrofluorometer (Fluorolog-3,
Jobin Yvon, France) at room temperature.
Porcine iliac artery endothelial cells (PIECs) were
obtained from the Institute of Biochemistry and Cell
Biology (Chinese Academy of Sciences). All the culture
media and reagents used in cytotoxicity tests were pur-
chased from Gibco Life Technologies (USA). PIECs were
seeded in 96-well flat-bottom microassay plates at a con-
centration of 2 × 10
4 cells/mL and cultured with 200 μL/
well Dulbecco’s Modified Eagle’s Medium (DMEM) with
10% fetal serum, 100 U/mL penicillin, and 100 U/mL
streptomycin for 48 h in a humidified incubator (BB-15,
Heraeus, Germany) with 5% CO2 at 37°C. The samples
were diluted with DMEM without fetal bovine serum at a
concentration of 6 mg/mL. Then, 50, 100, and 150 μLo f
each sample solution was added into each well, and the
cells were cultured for 24 h. To evaluate cytotoxicity, cell
viability was quantified using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay (Sigma, USA) and
Enzyme-labeled Instrument (MK3, Thermo, USA). Data
were measured in three independent parallel experiments,
and all data points were plotted as means ± standard
deviation (SD) (n =3 ) .
The typical drug loading and in vitro drug release
experiments were performed as follows: 0.5 g of dried
powder of Eu
3+:ACP porous nanospheres was added
into 50 mL hexane solution with an ibuprofen concen-
tration of 40 mg/mL. The suspension was then stirred
for 24 h in a sealed vessel at 37°C. The Eu
3+:ACP por-
ous nanospheres with loaded drug was centrifuged, and
2 mL supernatant was analyzed by UV-Vis absorption
spectroscopy at a wavelength of 263 nm to calculate the
ibuprofen storage. The drug loaded Eu
3+:ACP porous
nanospheres were washed with fresh hexane, dried at
60°C in air, and compacted into disks (0.3 g each, dia-
m e t e r1 0m m )a tap r e s s u r eo f3M P a .E a c hd i s kw a s
immersed into 200 mL of SBF at 37°C under shaking at
a constant rate using a desk-type oscillator (THI-92A,
China). Two milliliter of solution was removed for
UV-Vis analysis at 263 nm at given time intervals to
measure the amount of ibuprofen released, and this
quantity of solution was replaced with the same volume
of fresh SBF.
Transmission electron microscopy (TEM) micrographs
were obtained using a JEOL JEM 2100 field emission
electron microscope. X-ray diffraction (XRD) patterns
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fractometer with a graphite monochromator (Cu Ka
radiation, l = 1.54178 Å). Thermogravimetry (TG)
curves were obtained at a heating rate of 10°C in nitro-
gen using a STA 409/PC simultaneous thermal analyzer
(Netzsch, Germany). The Brunauer-Emmett-Teller
(BET) surface area and pore size distribution were mea-
sured with an accelerated surface area and porosimetry
system (ASAP 2010).
Results and discussion
The morphology of the as-prepared hybrid ACP/PLA-
mPEG and ACP were investigated with TEM (Figure 1).
From Figure 1a, one can see that the as-prepared hybrid
ACP/PLA-mPEG consists of nanoparticles with dia-
meters in the range of 10-60 nm. In some cases, nano-
particles with a porous structure were also observed as a
minor product. The selected area electron diffraction
pattern of the as-prepared ACP/PLA-mPEG hybrid
nanoparticles shows an electron diffraction pattern of
amorphous structure (inset of Figure 1a). In contrast,
the TEM micrograph of ACP prepared by microwave-
solvothermal treatment of ACP/PLA-mPEG hybrid
nanoparticles in DMF presents nanospheres with a por-
ous structure (Figure 1b). The magnified TEM image
(inset of Figure 1b) of a single ACP nanosphere shows
the nanopores in the nanosphere. The sizes of ACP por-
ous nanospheres are similar to those of ACP/PLA-
mPEG hybrid nanoparticles, indicating no significant
growth of ACP porous nanospheres during microwave-
solvothermal treatment of hybrid ACP/PLA-mPEG in
DMF. The XRD pattern of the as-prepared ACP/PLA-
mPEG hybrid nanoparticles (Figure 2a) shows no dis-
cernable peaks of crystalline calcium phosphate but a
characteristic hump of amorphous phase at around 2θ =
30°, indicating that the sample consisted of ACP [44].
Similarly, the XRD pattern of ACP porous nanospheres
(Figure 2b) indicates that the sample consisted of ACP,
too. Energy dispersive spectroscopy (EDS) measure-
ments were also performed to analyze the chemical
composition of the sample. The EDS data show that the
chemical composition of the sample is essentially uni-
f o r mi nt h es a m p l e .T h em o l a rr a t i oo fC at oPw a s
measured to be 1.41, and the molar ratio of (Eu + Ca)
to P was 1.49. The molar ratio of Eu
3+ to Ca
2+ was
5.3%, which is close to the nominal composition.
In order to determine the content of PLA-mPEG in
the ACP/PLA-mPEG hybrid nanoparticles, TG analysis
was employed. The TG curve of ACP/PLA-mPEG
hybrid nanoparticles is displayed in Figure 3; the weight
loss before about 100°C can be assigned to the adsorbed
water, while the weight loss between 100 and 425°C is
caused by the decomposition of the polymer segments.
For the TG curve of ACP porous nanospheres, the
weight loss is also caused by adsorbed water and crystal
water. On the basis of the analyses of TG curves, the
total weight losses of ACP/PLA-mPEG hybrid nanopar-
ticles and ACP porous nanospheres are about 21.9 and
10%, respectively. The weight percentage of PLA-mPEG
in the as-prepared ACP/PLA-mPEG hybrid nanoparti-
cles is estimated to be approximately 11.9%.
It was reported that the negatively charged oxygen
atoms of C-O-C groups in PEG could interact with
divalent cations such as Ca
2+ via electrostatic attraction
[45,46], and hence, the Ca
2+/PEG complex was formed.
The chemical structure of PLA-mPEG is illustrated in
Figure 4a; we propose that Ca
2+ ions can bind with PEG
segments of PLA-mPEG. Therefore, the formation of
ACP/PLA-mPEG hybrid nanoparticles may follow a pos-
sible mechanism described in Figure 4b. As is depicted,
during the reaction process, PLA-mPEG/Ca
2+ complex
micelles first form, the calcium phosphate precipitation
reaction takes place on the PLA-mPEG micelles, and
then the resulting ACP nanoparticles aggregate on the

Figure 1 TEM micrographs: (a) the as-prepared ACP/PLA-mPEG hybrid nanoparticles; and (b) ACP porous nanospheres.
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The polymer segments can act as the template and have
a steric effect, the rapid growth of ACP can be inhibited,
and the sizes of the ACP precipitate are confined to the
nanometer scale range. During microwave-solvothermal
treatment of ACP/PLA-mPEG hybrid nanoparticles in
DMF, the dissolution of the polymer PLA-mPEG occurs
and the nanopores form in ACP, resulting in the forma-
tion of ACP porous nanospheres.
The morphology of the as-prepared europium-doped
Eu
3+:ACP porous nanospheres were investigated with
TEM (Figure 5a, b) at the doping percentage of 5 mol%
Eu
3+. From Figure 5, one can see that the as-prepared
product consists of porous nanospheres, similar to the
undoped ACP porous nanospheres. In a few cases, the
nanosphere with a large pore in the center was also
observed, as shown in Figure 5b. These results support
the proposed formation mechanism shown in Figure 4b.
Figure 5c, d exhibits the N2 adsorption-desorption
isotherm and the corresponding Barrett-Joyner-Halenda
(BJH) pore size distribution curve of Eu
3+:ACP porous
nanospheres. According to the International Union of
Pure and Applied Chemistry, it can be classified as a
type-IV isotherm loop which is the characteristic of the
porous structure [47]. The BET-specific surface area
(SBET), the BJH desorption cumulative pore volume (VP),
and the average pore size are 126.7 m
2/g, 0.53 cm
3/g,
and 16.7 nm, respectively.
PL excitation and emission spectra of Eu
3+:ACP
(5 mol% Eu
3+) porous nanospheres measured at room
temperature are shown in Figure 6a. To investigate the
effect of the dopant content on PL, the concentration of
Eu
3+ dopant varied in the range of 1 to 10 mol%. As
shown in Figure 6a, the concentration of Eu
3+ dopant
had almost no effect on the wavelength of emission
peaks, but the PL intensity changed considerably by
varying Eu
3+ concentrations. Three emission peaks
appeared at about 590, 612, and 650 nm at an excitation
of 393 nm. The most intense peak at 612 nm corre-
sponds to the
5D0 ®
7F2 transition within Eu
3+ ions,
while other peaks at 590 and 650 nm correspond to
5D0 ®
7F1 and
5D0 ®
7F3 transitions, respectively. The
inset of Figure 6a displays the PL emission intensity at
612 nm as a function of the Eu
3+ concentration, and the
highest PL emission intensity was observed at 5 mol%
Eu
3+ doping. Under irradiation by UV lamp (365 nm),
both powders of Eu
3+:ACP (5 mol% Eu
3+)p o r o u sn a n o -
spheres and dispersed suspension in deionized water
show strong orange PL, as shown in Figure 6b, c.
The nanostructures containing optically active rare
earth ions have been of great interest in both funda-
mental studies and biomedical applications [1]. It is
important to investigate the cytotoxicity of the rare
earth-doped ACP porous nanospheres with endothelial
cells, because these nanostructures have potential to be
used in drug delivery and bio-imaging. The endothelial
cells are a specialized type of epithelial cells which form
the inner layer of blood vessels, and they are usually in
contact with the biomaterials such as drug carriers.
Therefore, the endothelial cells were chosen for the
cytotoxicity study. Cell viability results (Figure 7) reveal
that there were no cytotoxicity when the cells were sub-
jected to ACP/PLA-mPEG hybrid nanoparticles, ACP
porous nanospheres, and Eu
3+-doped ACP porous
nanospheres at concentrations ranging from 0.3 to 0.9
mg/well. The high biocompatibility can be explained by
the chemical properties of these samples.
We investigated the drug loading and release beha-
viors of Eu
3+:ACP porous nanospheres using a typical
anti-inflammatory drug, ibuprofen. The drug loading
capacity of Eu
3+:ACP porous nanospheres was calculated
from the absorbance values of ibuprofen hexane solution
before and after drug loading. The drug loading capacity
10 20 30 40 50 60 70
b
2T (degree)
I
n
t
e
n
s
i
t
y
 
(
a
.
u
.
)
a
Figure 2 XRD patterns:(a) the as-prepared ACP/PLA-mPEG hybrid
nanoparticles; and (b) ACP porous nanospheres.
200 400 600 800
70
75
80
85
90
95
100
W
e
i
g
h
t
 
(
%
)
Temperature 
o
C
21.9 %
10.0 %
a
b
Figure 3 TG curves: (a) the as-prepared ACP/PLA-mPEG hybrid
nanoparticles; and (b) ACP porous nanospheres.
Chen et al. Nanoscale Research Letters 2011, 6:67
http://www.nanoscalereslett.com/content/6/1/67
Page 4 of 90.0 0.2 0.4 0.6 0.8 1.0
0
100
200
300
400
500
V
o
l
u
m
e
 
A
d
s
o
r
b
e
d
 

c
m
3
/
g

Relative Pressure  P/P0
c
0 2 04 06 08 0 1 0 0
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
d
V
/
d
D
 

c
m
3
g
-
1
n
m
-
1

Pore Size (nm)
d
Figure 5 Characterization of the as-prepared Eu
3+:ACP (5 mol% Eu
3+) porous nanospheres: (a, b) TEM micrographs;
(c) N2 adsorption-desorption isotherm; and (d) BJH pore size distribution curve.
Figure 4 Illustration of the strategy for the preparation of ACP/PLA-mPEG hybrid nanoparticles and ACP porous nanospheres: (a)
Chemical structure of PLA-mPEG and (b) the proposed formation mechanism of ACP/PLA-mPEG hybrid nanoparticles and ACP porous
nanospheres.
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3+:ACP porous nanospheres reached 70 mg/g
carrier.
We also investigated the drug release behavior of Eu
3+:
ACP porous nanospheres in SBF. Figure 8a shows the
drug release behavior of the disk composed of ibuprofen-
loaded Eu
3+:ACP porous nanospheres in SBF. The cumu-
lative release amounts of ibuprofen from the disk were
about 30, 40, 60, and 80% at the release times of 2, 4, 10,
and 24 h, respectively. The final release amount reached
about 96% at 120 h. In the sample preparation process,
Figure 6 PL properties of Eu
3+:ACP porous nanospheres: (a) Room-temperature excitation and PL emission spectra of Eu
3+:ACP porous
nanospheres; (b) the PL of the powder of Eu
3+:ACP (5 mol% Eu
3+) porous nanospheres under UV irradiation at 365 nm; and (c) the PL of Eu
3+:
ACP (5 mol% Eu
3+) porous nanospheres dispersed in deionized water under UV irradiation at 365 nm.
Figure 7 Viabilities of PIECs which were cultured for 24 h with ACP/PLA-mPEG hybrid nanoparticles, ACP porous nanospheres, and 5
mol% Eu
3+-doped ACP porous nanospheres at concentrations ranging from 0.3 to 0.9 mg/well.
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3+:ACP porous nanospheres and some
agglomerated nanoparticles were formed. The experi-
mental results of drug loading and release can be under-
stood as due to the holistic behaviors of the sample
consisting of dispersed Eu
3+:ACP porous nanospheres
and some agglomerated nanoparticles. One can see that
the ibuprofen-loaded porous Eu
3+:ACP nanosphere disk
showed a slow and sustained release of ibuprofen, which
could avoid the explosive release of ibuprofen and pro-
long the drug effect.
The inset of Figure 8a shows a relationship between
the cumulative amount of released drug and the release
time for the Eu
3+:ACP porous nanosphere drug delivery
system. The cumulative amount of released drug (C) has
a linear relationship with the natural logarithm of
release time (ln(t)), instead of the square root of time. A
formula can be inferred for the drug release process of
Eu
3+:ACP porous nanospheres in SBF as follows:
CAk l n t =+ () (1)
This result is similar to that of our previous report on
the drug release system of porous microspheres of cal-
cium silicate hydrate [48]. For the drug delivery system
of Eu
3+:ACP porous nanospheres, the constant values of
A and k are determined to be 15.47 and 19.46, respec-
tively, with a regression factor of 0.999. Figure 8b shows
the XRD pattern of the drug delivery system of Eu
3+:
ACP porous nanospheres after drug release in SBF,
from which one can see that the product after drug
release was HAp instead of ACP, indicating that the
phase transformation from ACP to HAp occurred dur-
ing the drug release process in SBF.
It is well acknowledged that the Higuchi model (C =
K·t
1/2) can well describe the kinetics of drug release
from carrier materials [49-51], with a linear relationship
between the cumulative amount of the released drug (C)
and the square root of time (t
1/2), and that the drug
release is governed by a diffusion process. However, for
the drug delivery system of Eu
3+:ACP porous nano-
spheres, Eu
3+:ACP porous nanospheres are bioactive,
and they can transform from ACP to HAp in SBF solu-
tion during the drug release process. Therefore, for the
drug delivery system of Eu
3+:ACP porous nanospheres
in SBF, the drug release kinetics is different from that of
the model for common carrier materials.
In a previous study [28], the authors prepared HAp
nanostructured porous hollow ellipsoidal capsules which
were constructed by nanoplate networks using inorganic
CaCO3 template. CaCO3 ellipsoids were synthesized by
the reaction between Ca(CH3COO)2 and NaHCO3 in
mixed solvents of water and ethylene glycol at room
temperature, and they were used as the Ca
2+ source and
cores. Then, the PO4
3- source was added to react with
CaCO3 to form a HAp shell on the surface of CaCO3
ellipsoids. Dilute acetic acid was used to remove the
remaining CaCO3 cores. The drug loading and release
behaviors of HAp hollow ellipsoidal capsules were also
investigated. The ibuprofen-loaded HAp hollow ellip-
soidal capsules showed a slow and sustained release of
ibuprofen in SBF. A linear relationship between the
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Figure 8 Drug release and PL properties of ibuprofen-loaded
Eu
3+:ACP porous nanospheres: (a) The drug release curve in SBF
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3+:ACP porous
nanospheres, and the inset shows the cumulative drug release
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square root of time was found for the first 12 h. Com-
pared with HAp nanostructured hollow ellipsoidal cap-
sules, the Eu
3+:ACP porous nanosphere drug delivery
system also showed a slow and sustained drug release
profile. However, the IBU/Eu
3+:ACP porous nano-
sphere drug delivery system exhibited a faster drug
release rate than that of HAp nanostructured hollow
ellipsoidal capsules. On the other hand, the drug
release kinetics is different for the two drug delivery
systems. For the IBU/Eu
3+:ACP porous nanosphere
drug delivery system, the cumulative amount of the
released drug has a linear relationship with the natural
logarithm of release time (ln(t)), instead of the square
root of time. However, for IBU/HAp nanostructured
hollow ellipsoidal capsule drug delivery system, a linear
relationship between the cumulative amount of the
released ibuprofen and the square root of time was
found. The different drug release properties for the
two drug delivery systems may be explained by the dif-
ferent chemical compositions, structures, and morphol-
ogies of the two samples.
Figure 8c shows PL emission spectra of drug-loaded
Eu
3+:ACP porous nanospheres before and after drug
release. The characteristic emission peaks are still
obvious in the emission spectra for both the samples.
There were essentially no shifts in the spectral positions
for the characteristic emission peaks, but the PL peak
relative intensity and the shape of peaks changed after
drug loading. The change of PL properties may be
explained by the effect of ibuprofen. However, after in
vitro drug release, it is worth noting that the intensities of
the emission peaks increased. This phenomenon may be
explained by the transformation of carrier material from
ACP to HAp during the process of drug release in SBF.
The as-prepared Eu
3+:ACP porous nanospheres have a
porous structure, which is favorable for a sustained drug
release. The Eu
3+:ACP porous nanospheres empowered
by luminescent properties show a great potential for
applications in both drug delivery and in vivo bioima-
ging. Considering the biocompatible and biodegradable
nature, Eu
3+:ACP porous nanospheres are a new kind of
promising biomaterial.
Conclusions
Calcium phosphate is the most important inorganic
constituent of biological hard tissues. ACP, as one of
the most important calcium phosphates, is bioactive
with biocompatibility and biodegradability. In this study,
the authors report a facile method for the preparation of
ACP/PLA-mPEG hybrid nanoparticles, which were suc-
cessfully used as the precursor for the preparation of
ACP porous nanospheres. PL function of ACP porous
nanospheres was achieved by europium doping. The
BET-specific surface area, the BJH-desorption cumula-
tive pore volume, and the average pore size were 126.7
m
2/g, 0.53 cm
3/g, and 16.7 nm, respectively, for the
Eu
3+:ACP porous nanospheres. The experimental results
of PL, cytotoxicity, as well as in vitro drug loading and
release showed that the as-prepared Eu
3+:ACP porous
nanospheres were biocompatible and bioactive with
favorable properties of PL, drug loading and drug
release, implying that Eu
3+:ACP porous nanospheres are
a new kind of promising biomaterial with bi-functions
of both luminescence and drug delivery.
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